Table 2.
Compare the change of key clinical features between standard treatment group and ARNI group
| Items | Standard treatment (N = 525) | ARNI (N = 253) | P value |
|---|---|---|---|
| △NYHA, No. (%) | 0.827 | ||
| Reduced | 9 (1.7) | 3 (1.2) | |
| Unchanged | 502 (95.6) | 244 (96.4) | |
| Elevated | 14 (2.7) | 6 (2.4) | |
| △LVEF, No. (%) | 0.002 | ||
| Reduced | 36 (6.9) | 35 (13.8) | |
| Unchanged | 387 (73.7) | 162 (64.0) | |
| Elevated | 102 (19.4) | 56 (22.1) | |
| △LVEDD, No. (%) | 0.025 | ||
| Reduced | 55 (10.5) | 44 (17.4) | |
| Unchanged | 401 (76.4) | 177 (70.0) | |
| Elevated | 69 (13.1) | 32 (12.6) | |
| △DBP, median (IQR) | -5.00 (-14.50-3.00) | -6.00 (-17.00-2.00) | 0.228 |
| △SBP, median (IQR) | -7.00 (-20.00-4.14) | -10.00 (-24.00-1.50) | 0.016 |
| △Serum creatinine, median (IQR) | 0.00 (0.00–0.00) | 0.00 (0.00–0.00) | 0.275 |
| △eGFR, median (IQR) | 0.00 (0.00-0.85) | 0.00 (0.00–0.00) | 0.600 |
| △NT-proBNP, median (IQR) | 0.00 (-768.76-0.00) | 0.00 (-2185.00-0.00) | 0.010 |
| △serum potassium, median (IQR) | 0.00 (-0.17-0.50) | 0.09 (-0.05-0.52) | 0.089 |
△post treatment level - baseline level. NYHA, New York Heart Association; LVEF, left ventricular ejection fraction; LVEDD, left ventricular end-diastolic diameter; DBP, diastolic blood pressure; IQR, interquartile range; SBP, systolic blood pressure; eGFR, estimated glomerular filtration rate; NT-proBNP, pro-brain natriuretic peptide